在乳腺癌中,APOBEC3突变驱动治疗耐药性
Avantika Gupta1, Andrea Gazzo2, Pier Selenica2
1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nature genetics
|May 16, 2025
概括
阿波蛋白B mRNA编辑酶催化多类3 (APOBEC3) 酶活性驱动的遗传变化导致对乳腺癌疗法的耐药性. 这一发现凸显了APOBEC3作为克服治疗耐药性的潜在生物标志物和治疗标.
科学领域:
- 遗传学 是一个遗传学.
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 获得的基因变异是转移性乳腺癌中对内分泌和向疗法的抵抗的主要原因.
- 驱动这些耐药性转变的特定生物过程在很大程度上是未知的.
研究的目的:
- 确定转移性乳腺癌中治疗耐药性的基因突变过程.
- 调查阿波利波蛋白B mRNA编辑酶催化型多类3 (APOBEC3) 在驱动这些遗传变异和治疗耐药性的作用.
主要方法:
- 分析了3,880个临床注释患者样本的瘤正常测序数据.
- 乳腺癌模型的全基因组测序和对联的初级转移样本.
- 评估突变特征及其与临床结果和治疗耐药性的相关性.
主要成果:
- 与APOBEC3酶相关的突变特征在治疗后的激素受体阳性乳腺癌中经常被发现和丰富.
- 在接受抗雌激素加CDK4/6抑制剂治疗的患者中,APOBEC3相关的特征与较短的无进展存活率相关.
- 活性APOBEC3突变被证明通过RB1损失等变化促进治疗耐药性,即使在治疗前的样本中也存在APOBEC3活性的证据.
结论:
- 在乳腺癌中,APOBEC3突变是治疗耐药性的重要媒介.
- APOBEC3的活性在乳腺癌的演变中起着普遍的作用,并导致治疗失败.
- 向APOBEC3可能是克服乳腺癌内分泌和向治疗耐药性的新策略.
更多相关视频
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
10.6K
12:28Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
Published on: January 11, 2019
7.3K
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Mutagenicity and Carcinogenicity
1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mismatch Repair
4.8K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
4.8K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
